No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 940 | 1,164 | 1,336 | 1,300 | 1,500 | 1,640 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 116 | 156 | 185 | 207 | 227 | 265 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in Nanchang, China, in 1997, Jiangxi Sanxin Medtec Co., Ltd. is a medical technology company dedicated to the research, development, manufacturing, sales, and servicing of medical devices. The company operates both domestically and internationally, offering a wide array of products across several key therapeutic categories: Renal Dialysis and Blood Purification: This segment includes advanced centralized dialysate supply systems, hemodialysis water preparation units, and hemodialysis machines. It also provides a variety of consumables such as specialized nursing kits, central venous catheter packs, arteriovenous spikes, HDF accessory tubing, dialysate filters, hemodialysis powders and concentrates, hollow fiber hemodialyzers, sterile blood circuits, and tubing sets for hemodialysis. Infusion and Transfusion Equipment: The company supplies various infusion and transfusion sets, including light-resistant, TPE precise filter, and auto-stop fluid precise filter types, alongside standard transfusion sets, catheter infusion sets, and precise filter light-resistant options. Injection Devices: Its portfolio encompasses diverse syringes, such as insulin, dispenser, sterile, auto-disable, and fixed-dose immunization syringes. This category also features hypodermic needles, innovative needleless injection systems, and pneumatic syringes. Intravenous Catheterization Products: Offerings include various indwelling catheters like straight, Y-type, and closed IV catheters, positive pressure IV catheters, central venous catheter kits, extension tubes with three-way valves, and heparin caps. General Medical Supplies: Additional products include blood microembolus filters, disposable extracorporeal circulation tubing kits, cold cardioplegic solution perfusion apparatus, blood containers, medical-grade surgical masks, disinfectants, and alcohol pads.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jiangxi Sanxin Medtec Co.,Ltd. (300453.SZ)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in Nanchang, China, in 1997, Jiangxi Sanxin Medtec Co., Ltd. is a medical technology company dedicated to the research, development, manufacturing, sales, and servicing of medical devices. The company operates both domestically and internationally, offering a wide array of products across several key therapeutic categories: Renal Dialysis and Blood Purification: This segment includes advanced centralized dialysate supply systems, hemodialysis water preparation units, and hemodialysis machines. It also provides a variety of consumables such as specialized nursing kits, central venous catheter packs, arteriovenous spikes, HDF accessory tubing, dialysate filters, hemodialysis powders and concentrates, hollow fiber hemodialyzers, sterile blood circuits, and tubing sets for hemodialysis. Infusion and Transfusion Equipment: The company supplies various infusion and transfusion sets, including light-resistant, TPE precise filter, and auto-stop fluid precise filter types, alongside standard transfusion sets, catheter infusion sets, and precise filter light-resistant options. Injection Devices: Its portfolio encompasses diverse syringes, such as insulin, dispenser, sterile, auto-disable, and fixed-dose immunization syringes. This category also features hypodermic needles, innovative needleless injection systems, and pneumatic syringes. Intravenous Catheterization Products: Offerings include various indwelling catheters like straight, Y-type, and closed IV catheters, positive pressure IV catheters, central venous catheter kits, extension tubes with three-way valves, and heparin caps. General Medical Supplies: Additional products include blood microembolus filters, disposable extracorporeal circulation tubing kits, cold cardioplegic solution perfusion apparatus, blood containers, medical-grade surgical masks, disinfectants, and alcohol pads.